Is dabrafenib a medically insured drug?

Dabrafenib is a targeted drug targeting BRAF V600 mutation. It is mainly used to treat specific types of cancers with BRAF gene mutations, such as melanoma and non-small cell lung cancer. Dabrafenib is a medical insurance drug that has been approved for marketing in my country. According to reports, the original version of dabrafenib on the domestic market provides two specifications for consumers to choose from, namely 75mg 120 tablets and 50mg 120 tablets. After being included in medical insurance, the price of 75mg medicine is about 12,000 yuan. To sum up, dabrafenib is not only a medical insurance drug, but also significantly reduces the patient’s financial burden through medical insurance reimbursement. It is understood that there are more cost-effective generic versions of dabrafenib overseas. If patients have more questions in this regard, please consult a regular overseas medical consultant.